Strides Pharma arm gets Rs 525-crore deferred consideration for Aussie deal, shares spike
Strides Pharma's step-down subsidiary in Singapore received AUD 94 million or Rs 525 crore as the deferred consideration for the sale of the Company’s Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet, the firm said in an exchange filing.
Strides Pharma arms gets USFDA approval for potassium-deficiency drug
The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte Ltd, Singapore, is for potassium chloride oral solution of strength 40 mEq/15mL (20 per cent), Strides Pharma Science (Strides) said in a regulatory filing.
STAR - Daily chart, looks good as it is reversing from double bottom, Cmp 333-334, it can be considered for medium to long term of 5-8 years for better returns, sl can be below 270 on weekly closing basis. (Disclaimer - For study purpose only)
Glenmark, Strides Pharma, Cipla recall products in the US
The USFDA noted in its report that the company, a subsidiary of Mumbai-based drug firm, is recalling the affected lot due to "blister package issues." The lot was produced at Glenmark's Pithampur (Madhya Pradesh) based manufacturing facility. The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year.
Stride Pharma Science Q1 Results: Net loss narrows to Rs 163 crore
Revenue from the US business in the June quarter stood at Rs 355.2 crore, up from Rs 301.6 crore last year.Similarly, the company said its revenues from Other Regulated Markets (ORM) was at Rs 304.7 crore in the first quarter of FY23. The same stood at Rs 223.2 crore in the corresponding period last fiscal
Strides Pharma recalls over 6 lakh bottles of blood pressure treatment tablets in US
As per the latest enforcement report by the US Food and Drug Administration (USFDA), the company, which is a unit of Bengaluru-headquartered Strides Pharma Science, is recalling 6,78,829 bottles of the blood pressure lowering drug in the US market.
Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs
In the letter written on May 13, Arun Kumar, Founder and Director of Stelis Biopharma Limited, said that after the prime minister had requested the industry to gear up to tackle the pandemic, the firm invested over Rs 700 crore to set up a state-of the-art vaccine manufacturing facility within six months despite the COVID-19-induced restrictions and quickly commenced the production of Sputnik Light.